Format

Send to

Choose Destination
Am J Vet Res. 2013 Oct;74(10):1327-32. doi: 10.2460/ajvr.74.10.1327.

Pharmacokinetics and safety of silibinin in horses.

Author information

1
Department of Clinical Sciences, College of Veterinary Medicine and Biological Sciences, Colorado State University, Fort Collins, CO, 80523.

Abstract

OBJECTIVE:

To determine the oral bioavailability, single and multidose pharmacokinetics, and safety of silibinin, a milk thistle derivative, in healthy horses.

ANIMALS:

9 healthy horses.

PROCEDURES:

Horses were initially administered silibinin IV and silibinin phospholipid orally in feed and via nasogastric tube. Five horses then consumed increasing orally administered doses of silibinin phospholipid during 4 nonconsecutive weeks (0 mg/kg, 6.5 mg/kg, 13 mg/kg, and 26 mg/kg of body weight, twice daily for 7 days each week).

RESULTS:

Bioavailability of orally administered silibinin phospholipid was 0.6% PO in feed and 2.9% via nasogastric tube. During the multidose phase, silibinin had nonlinear pharmacokinetics. Despite this, silibinin did not accumulate when given twice daily for 7 days at the evaluated doses. Dose-limiting toxicosis was not observed.

CONCLUSIONS AND CLINICAL RELEVANCE:

Silibinin phospholipid was safe, although poorly bio-available, in horses. Further study is indicated in horses with hepatic disease.

PMID:
24066917
DOI:
10.2460/ajvr.74.10.1327
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center